TY - JOUR
T1 - Transcatheter aortic valve implantation in patients with bicuspid valve morphology
T2 - a roadmap towards standardization
AU - Xiong, Tian Yuan
AU - Ali, Walid Ben
AU - Feng, Yuan
AU - Hayashida, Kentaro
AU - Jilaihawi, Hasan
AU - Latib, Azeem
AU - Lee, Michael Kang Yin
AU - Leon, Martin B.
AU - Makkar, Raj R.
AU - Modine, Thomas
AU - Naber, Christoph
AU - Peng, Yong
AU - Piazza, Nicolo
AU - Reardon, Michael J.
AU - Redwood, Simon
AU - Seth, Ashok
AU - Sondergaard, Lars
AU - Tay, Edgar
AU - Tchetche, Didier
AU - Yin, Wei Hsian
AU - Chen, Mao
AU - Prendergast, Bernard
AU - Mylotte, Darren
N1 - Funding Information:
We thank the National Natural Science Foundation of China (81970325, 82170375 and 82102129) and West China Hospital “1·3·5” Discipline of Excellence Project — “Percutaneous transcatheter aortic valve implantation” and “Mechanisms of aortic stenosis and the clinical applications” for supporting this project, and Yi Zhang (Department of Cardiology, West China Hospital, Sichuan University, China) for assistance with the literature review.
Funding Information:
Y.F. is a consultant/proctor for Peijia Medical and Venus MedTech. K.H. is a proctor for Edwards Lifesciences and Medtronic. H.J. is a consultant to Boston Scientific, Edwards Lifesciences and Medtronic, and has received grant and research support from Abbott Vascular, Edwards Lifesciences and Medtronic. A.L. is an advisory board member for Abbott and Medtronic. M.K.-Y.L. is a proctor for Edwards Lifesciences and Medtronic. M.B.L. has received institutional research support from Abbott, Boston Scientific, Edwards Lifesciences and Medtronic, and is a consultant or advisory board member for Abbott, Boston Scientific, Gore, Medtronic and Meril Life. R.R.M. has received research grants from Abbott, Boston Scientific, Edwards Lifesciences and Medtronic, and has received personal fees from Edwards Lifesciences for travel. T.M. is a consultant for Abbott, Boston Scientific, Cephea, Edwards Lifesciences, GE Healthcare, Medtronic and Microport, is a proctor for Medtronic, and receives speaker fees from Medtronic. C.N. has received lecture fees from Abbott Vascular, Boston Scientific and Medtronic, and has served on the advisory boards of Abbott Vascular and Boston Scientific. N.P. is a consultant and proctor for Medtronic and Peijia Medical. M.J.R. serves on an advisory board for Medtronic. S.R. has received speaker fees from Edwards Lifesciences and has served as an international advisory board member for Medtronic. A.S. is an adviser/speaker for Abbott Vascular, Boston Scientific, Medtronic and Meril Lifesciences, and is a proctor for Medtronic and Meril Lifesciences. L.S. has received consulting fees and institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic and Symetis. D.T. is a proctor for Boston Scientific, Edwards Lifesciences and Medtronic. M.C. is a consultant/proctor for Peijia Medical and Venus MedTech. B.P. has received institutional educational and research grants from Edwards Lifesciences and has received speaker/consultancy fees from Abbott, Anteris, Edwards Lifesciences, Medtronic and Microport. D.M. is a proctor and consultant for Medtronic and Microport and is a consultant for Boston Scientific. The other authors declare no competing interests.
Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022
Y1 - 2022
N2 - Indications for transcatheter aortic valve implantation (TAVI) have expanded in many countries to include patients with aortic stenosis who are at low surgical risk, and a similar expansion to this cohort is anticipated elsewhere in the world, together with an increase in the proportion of patients with bicuspid aortic valve (BAV) morphology as the age of the patients being treated decreases. To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.
AB - Indications for transcatheter aortic valve implantation (TAVI) have expanded in many countries to include patients with aortic stenosis who are at low surgical risk, and a similar expansion to this cohort is anticipated elsewhere in the world, together with an increase in the proportion of patients with bicuspid aortic valve (BAV) morphology as the age of the patients being treated decreases. To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.
UR - http://www.scopus.com/inward/record.url?scp=85132161088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132161088&partnerID=8YFLogxK
U2 - 10.1038/s41569-022-00734-5
DO - 10.1038/s41569-022-00734-5
M3 - Article
AN - SCOPUS:85132161088
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
SN - 1759-5002
ER -